Riding High, Victoza Hopes To Gain Ground Over Popular DPP-4s With Label Change
FDA label now notes superior efficacy and greater weight loss for Novo Nordisk’s injectable GLP-1 receptor agonist Victoza vs. Mercks’ DPP-4 inhibitor Januvia. Superiority would be expected for a GLP-1, but label still has potential to encourage earlier use of the class.
You may also be interested in...
Takeda’s beleaguered Nesina (alogliptin) becomes the fourth DPP-4 inhibitor approved by FDA for diabetes; it remains to be seen whether the drug can find its place in a highly competitive space that continues to be controlled by Merck’s first-to-market blockbuster Januvia.
Sanofi and Lilly, latecomers to the rising class of GLP-1 diabetes drugs, may not have much to differentiate their drugs from other offerings. But at investor forums at the American Diabetes Association meeting, they highlighted some possibilities, including hypertension data and combination therapies.
Latest “complete response” letter for Takeda’s DPP-4 inhibitor is “not specific” to cardiovascular outcomes. But the delay does not bode well for entry into the crowded DPP-4 space.